{"id":39815,"date":"2025-08-21T11:27:36","date_gmt":"2025-08-21T03:27:36","guid":{"rendered":"https:\/\/flcube.com\/?p=39815"},"modified":"2025-08-21T11:27:37","modified_gmt":"2025-08-21T03:27:37","slug":"ascentage-pharma-reports-h1-2025-financial-results-shows-strong-growth-in-olverembatinib-sales","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39815","title":{"rendered":"Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales"},"content":{"rendered":"\n<p>China-based <strong>Ascentage Pharma (NASDAQ: AAPG; HKG: 6855)<\/strong> reported its financial results for the first half of 2025 on August 21. The company&#8217;s revenue reached RMB 234 million, reflecting a year-on-year decline of 71.6%. This decrease was primarily attributed to the recognition of RMB 678 million in intellectual property revenue during the same period in 2024.<\/p>\n\n\n\n<p><strong>Olverembatinib Shows Strong Sales Growth<\/strong><br>Sales of <strong>olverembatinib (HQP1351)<\/strong> in the Chinese market reached RMB 217 million in H1 2025, marking a year-on-year increase of 92.5%. This growth was significantly bolstered by the inclusion of all approved indications for olverembatinib in China&#8217;s <strong>National Reimbursement Drug List (NRDL)<\/strong> since January 2025. The NRDL listing has enhanced the drug&#8217;s affordability and accessibility across the country.<\/p>\n\n\n\n<p>As of June 30, 2025, <strong>olverembatinib<\/strong> was available at 782 DTP (Direct-to-Patient) pharmacies and hospitals nationwide, representing a 17% increase compared to the same period in 2024. The number of hospitals with access to the drug grew from 201 to 295 year-over-year, reflecting a 47% expansion.<\/p>\n\n\n\n<p><strong>R&amp;D Investments and Financial Position<\/strong><br>The company&#8217;s research and development (R&amp;D) expenses rose to RMB 529 million, up 19% year-on-year. This increase was driven by higher outsourced R&amp;D costs aimed at advancing global clinical development programs.<\/p>\n\n\n\n<p>In July 2025, Ascentage Pharma completed a public fundraising round, securing net proceeds of RMB 1.37 billion. Combined with existing cash reserves, loan facilities, and projected future sales revenue, these funds are expected to cover operating expenses and capital expenditures until the end of 2027.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082100018_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025082100018_c.\"><\/object><a id=\"wp-block-file--media-6ad90848-ae92-48da-ae6f-a19d63da34a7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082100018_c.pdf\">2025082100018_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082100018_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6ad90848-ae92-48da-ae6f-a19d63da34a7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) reported its financial results for the first half&#8230;<\/p>\n","protected":false},"author":1,"featured_media":39817,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[200,27,985,3273],"class_list":["post-39815","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-ascentage-pharma","tag-finanical-reports","tag-hkg-6855","tag-nasdaq-aapg"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) reported its financial results for the first half of 2025 on August 21. The company&#039;s revenue reached RMB 234 million, reflecting a year-on-year decline of 71.6%. This decrease was primarily attributed to the recognition of RMB 678 million in intellectual property revenue during the same period in 2024.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39815\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales\" \/>\n<meta property=\"og:description\" content=\"China-based Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) reported its financial results for the first half of 2025 on August 21. The company&#039;s revenue reached RMB 234 million, reflecting a year-on-year decline of 71.6%. This decrease was primarily attributed to the recognition of RMB 678 million in intellectual property revenue during the same period in 2024.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39815\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-21T03:27:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-21T03:27:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39815#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39815\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales\",\"datePublished\":\"2025-08-21T03:27:36+00:00\",\"dateModified\":\"2025-08-21T03:27:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39815\"},\"wordCount\":249,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39815#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2101.webp\",\"keywords\":[\"Ascentage Pharma\",\"Finanical Reports\",\"HKG: 6855\",\"NASDAQ: AAPG\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39815#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39815\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39815\",\"name\":\"Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39815#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39815#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2101.webp\",\"datePublished\":\"2025-08-21T03:27:36+00:00\",\"dateModified\":\"2025-08-21T03:27:37+00:00\",\"description\":\"China-based Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) reported its financial results for the first half of 2025 on August 21. The company's revenue reached RMB 234 million, reflecting a year-on-year decline of 71.6%. This decrease was primarily attributed to the recognition of RMB 678 million in intellectual property revenue during the same period in 2024.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39815#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39815\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39815#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39815#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) reported its financial results for the first half of 2025 on August 21. The company's revenue reached RMB 234 million, reflecting a year-on-year decline of 71.6%. This decrease was primarily attributed to the recognition of RMB 678 million in intellectual property revenue during the same period in 2024.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39815","og_locale":"en_US","og_type":"article","og_title":"Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales","og_description":"China-based Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) reported its financial results for the first half of 2025 on August 21. The company's revenue reached RMB 234 million, reflecting a year-on-year decline of 71.6%. This decrease was primarily attributed to the recognition of RMB 678 million in intellectual property revenue during the same period in 2024.","og_url":"https:\/\/flcube.com\/?p=39815","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-21T03:27:36+00:00","article_modified_time":"2025-08-21T03:27:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39815#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39815"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales","datePublished":"2025-08-21T03:27:36+00:00","dateModified":"2025-08-21T03:27:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39815"},"wordCount":249,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39815#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2101.webp","keywords":["Ascentage Pharma","Finanical Reports","HKG: 6855","NASDAQ: AAPG"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39815#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39815","url":"https:\/\/flcube.com\/?p=39815","name":"Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39815#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39815#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2101.webp","datePublished":"2025-08-21T03:27:36+00:00","dateModified":"2025-08-21T03:27:37+00:00","description":"China-based Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) reported its financial results for the first half of 2025 on August 21. The company's revenue reached RMB 234 million, reflecting a year-on-year decline of 71.6%. This decrease was primarily attributed to the recognition of RMB 678 million in intellectual property revenue during the same period in 2024.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39815#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39815"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39815#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2101.webp","width":1080,"height":608,"caption":"Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39815#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39815"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39815\/revisions"}],"predecessor-version":[{"id":39818,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39815\/revisions\/39818"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39817"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}